A new series of Health Affairs health policy briefs, published with support from The Commonwealth Fund and Memorial Sloan Kettering’s Drug Pricing Lab, focuses on four of the key issues affecting prescription drug prices in the U.S.: expedited approval pathways, "orphan" drugs, biosimilar drugs, and patent settlements.
New Health Affairs Series on Drug Pricing
